clinical trial · NCT07533942
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
MeningiomaJZP3507
brief summary
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
started
Jun 1, 2026
primary completion
Oct 25, 2028
completion
Oct 16, 2031
last updated
Apr 16, 2026
official title
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol